Authors
Vivian Bi, Vibha Jawa, Marisa K Joubert, Arunan Kaliyaperumal, Catherine Eakin, Karen Richmond, Oscar Pan, Jilin Sun, Martha Hokom, Theresa J Goletz, Jette Wypych, Lei Zhou, Bruce A Kerwin, Linda O Narhi, Taruna Arora
Publication date
2013/10/1
Journal
Journal of pharmaceutical sciences
Volume
102
Issue
10
Pages
3545-3555
Publisher
Elsevier
Description
We describe a novel human immunoglobulin G2 (IgG2)-tolerant and immune-competent heterozygous mouse model (Xeno-het) developed by crossbreeding a human Ig-tolerized XenoMouse® with a C57BL/6J wild-type mouse. The Xeno-het mouse expresses both mouse and human immunoglobulin G (IgG) genes, resulting in B-cells expressing human and mouse IgG, and secretion of human and mouse Ig into serum. This model was utilized to evaluate the immunogenicity risk of aggregated and chemically modified human antibodies. The mice were tested for their ability to break tolerance to self-tolerant monomeric antibodies. Aggregates made by mechanical stirring elicited an anti-drug antibody (ADA) response, but did not induce a robust and long-term memory B and T-cell response. Chemically modified antibodies made by oxidation were only weak and transient inducers of an immune response, as …
Total citations
201320142015201620172018201920202021202220232024117109346563
Scholar articles